1. Home
  2. AIG vs ARGX Comparison

AIG vs ARGX Comparison

Compare AIG & ARGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo American International Group Inc. New

AIG

American International Group Inc. New

HOLD

Current Price

$85.77

Market Cap

43.9B

Sector

Finance

ML Signal

HOLD

Logo argenx SE

ARGX

argenx SE

HOLD

Current Price

$843.23

Market Cap

52.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AIG
ARGX
Founded
1919
2008
Country
United States
Netherlands
Employees
N/A
N/A
Industry
Life Insurance
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
43.9B
52.6B
IPO Year
N/A
2017

Fundamental Metrics

Financial Performance
Metric
AIG
ARGX
Price
$85.77
$843.23
Analyst Decision
Hold
Strong Buy
Analyst Count
14
19
Target Price
$88.38
$971.89
AVG Volume (30 Days)
4.9M
271.1K
Earning Date
02-10-2026
10-30-2025
Dividend Yield
2.10%
N/A
EPS Growth
N/A
N/A
EPS
5.51
23.27
Revenue
$27,120,000,000.00
$3,683,281,000.00
Revenue This Year
$1.74
$91.44
Revenue Next Year
$6.72
$36.90
P/E Ratio
$15.30
$33.59
Revenue Growth
2.52
92.98
52 Week Low
$69.24
$510.06
52 Week High
$88.07
$934.62

Technical Indicators

Market Signals
Indicator
AIG
ARGX
Relative Strength Index (RSI) 66.30 39.65
Support Level $86.13 $843.03
Resistance Level $86.78 $858.80
Average True Range (ATR) 1.71 13.64
MACD 0.06 -4.20
Stochastic Oscillator 77.20 22.60

Price Performance

Historical Comparison
AIG
ARGX

About AIG American International Group Inc. New

American International Group is one of the largest insurance and financial services firms in the world and has a global footprint. It operates through a wide range of subsidiaries that provide property, casualty, and life insurance. The company recently spun off its life insurance operations (Corebridge), but still retains a minority stake.

About ARGX argenx SE

Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.

Share on Social Networks: